How to Fight Insurance Denials for Cancer Treatment: A Patient Guide to Appeals That Work

Cancer treatment has advanced dramatically in the past decade—immunotherapy, CAR-T cell therapy, precision oral targeted drugs, antibody-drug conjugates, and genomic profiling now offer hope where once there was none. But insurers routinely deny coverage for these life-saving treatments, citing "experimental" status, lack of "medical necessity," or narrow interpretations of FDA labels. This guide explains why oncology denials are so common, which evidence insurers actually respect, and how to build an appeal that wins. It covers checkpoint inhibitors (Keytruda, Opdivo, Tecentriq), CAR-T (Kymriah, Yescarta), targeted oral therapies (Tagrisso, Imbruvica, Verzenio, Lorbrena, Krazati), antibody-drug conjugates (Enhertu, Trodelvy, Padcev, Elahere, Datroway), proton beam radiation, PET imaging, comprehensive genomic profiling (FoundationOne, Guardant360, MSK-IMPACT), and off-label use supported by the NCCN Compendium.

Why Insurers Deny Cancer Treatment

1. "Experimental / Investigational"

The insurer claims the drug or procedure lacks sufficient evidence, is "unproven," or remains under study—even when the treatment has full FDA approval, appears in national guidelines, and is considered standard of care by oncologists.

2. "Not Medically Necessary"

The plan argues that another, older (usually cheaper) treatment should be tried first, or that your specific biomarker, stage, or line of therapy does not meet their internal criteria—even when NCCN or your physician's judgment supports it.

3. "Off-Label / Not FDA-Approved for Your Cancer Type"

Many effective cancer treatments are used beyond their original FDA indication. Insurers deny these "off-label" uses unless the drug appears in certain compendia—most importantly, the NCCN Drugs & Biologics Compendium.

4. "Genomic Testing Not Covered / Too Broad"

Comprehensive next-generation sequencing panels (FoundationOne CDx, Guardant360 CDx, MSK-IMPACT, Tempus xT) are denied as "not medically necessary" or "research," even though they identify actionable mutations that guide FDA-approved targeted therapies.

5. "Radiation Modality Not Superior / Proton Therapy Experimental"

Proton beam therapy denials claim that intensity-modulated radiation therapy (IMRT) is adequate, despite clinical scenarios (pediatric tumors, base-of-skull, re-irradiation) where protons offer clear dosimetric advantages and lower toxicity.

The Citations Insurers Respect

Successful appeals cite the same sources insurance medical directors use. Below are the specific named references that carry weight in oncology peer-to-peer reviews and external appeals.

National Comprehensive Cancer Network (NCCN) Guidelines

• NCCN Clinical Practice Guidelines in Oncology (updated continuously; cite the version dated within the past 12 months for your cancer type—e.g., NCCN Non-Small Cell Lung Cancer v3.2024, NCCN Breast Cancer v5.2024).
• NCCN Drugs & Biologics Compendium (NCCN Compendium): the gold-standard reference for off-label oncology use. Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 and the Affordable Care Act, many commercial and Medicare plans are required to cover drugs listed with Category 1, 2A, or 2B recommendations in the NCCN Compendium for your specific cancer and clinical scenario.

FDA Approvals & Label Expansions

Cite the exact FDA approval date and indication. Examples from recent years:

• Tagrisso (osimertinib): FDA April 18, 2018, first-line EGFR-mutant NSCLC (FLAURA trial); adjuvant approval December 18, 2020 (ADAURA); chemotherapy combination February 16, 2024 (FLAURA2).
• Lazcluze (lazertinib) + Rybrevant (amivantamab): FDA August 19, 2024, first-line EGFR-mutant NSCLC (MARIPOSA trial).
• Lorbrena (lorlatinib): FDA March 3, 2021, first-line ALK-positive NSCLC (CROWN trial).
• Augtyro (repotrectinib): FDA November 15, 2023, ROS1-positive NSCLC; June 13, 2024, NTRK-positive solid tumors.
• Krazati (adagrasib): FDA December 12, 2022, KRAS G12C-mutant NSCLC (KRYSTAL-1); June 21, 2024, colorectal cancer with cetuximab (KRYSTAL-1 CRC cohort).
• Lumakras (sotorasib): FDA May 28, 2021, KRAS G12C NSCLC (CodeBreaK 100/200).
• Enhertu (trastuzumab deruxtecan, T-DXd): FDA August 5, 2022, HER2-low breast cancer (DESTINY-Breast04); April 5, 2024, HER2-ultra-low expansion (DESTINY-Breast06); plus HER2-positive NSCLC and gastric indications.
• Truqap (capivasertib) + fulvestrant: FDA November 16, 2023, HR+/HER2− breast cancer with PIK3CA/AKT1/PTEN alterations (CAPItello-291).
• Itovebi (inavolisib) + palbociclib + fulvestrant: FDA October 10, 2024, first-line HR+/HER2− PIK3CA-mutated metastatic breast cancer (INAVO120).
• Verzenio (abemaciclib): FDA September 28, 2017, metastatic breast cancer; October 12, 2021, adjuvant high-risk early breast cancer (monarchE).
• Kisqali (ribociclib): FDA March 13, 2017, HR+/HER2− MBC (MONALEESA-2/3/7); September 17, 2024, adjuvant high-risk EBC (NATALEE).
• Trodelvy (sacituzumab govitecan): FDA April 22, 2020, metastatic triple-negative breast cancer (ASCENT); February 3, 2023, HR+/HER2− MBC (TROPiCS-02).
• Datroway (datopotamab deruxtecan, Dato-DXd): FDA January 17, 2025, HR+/HER2− metastatic breast cancer (TROPION-Breast01).
• Padcev (enfortumab vedotin) + Keytruda: FDA December 15, 2023, first-line locally advanced/metastatic urothelial carcinoma (EV-302).
• Vyloy (zolbetuximab): FDA October 18, 2024, first-line HER2-negative gastric/gastroesophageal junction adenocarcinoma, CLDN18.2-positive (SPOTLIGHT/GLOW).
• Elahere (mirvetuximab soravtansine): FDA March 22, 2024 (full approval), FRα-positive platinum-resistant ovarian cancer (MIRASOL).
• Tivdak (tisotumab vedotin): FDA April 29, 2024 (full approval), recurrent/metastatic cervical cancer (innovaTV 301).
• Jemperli (dostarlimab) + Lenvima (lenvatinib): FDA August 1, 2024, first-line primary advanced/recurrent endometrial dMMR/MSI-H (RUBY); July 31, 2024, with carboplatin/paclitaxel for both dMMR and pMMR endometrial (RUBY).
• Fruzaqla (fruquintinib): FDA November 8, 2023, refractory metastatic colorectal cancer (FRESCO-2).
• Braftovi (encorafenib) + Erbitux (cetuximab): FDA April 8, 2020, BRAF V600E metastatic CRC (BEACON).

Landmark Trials (Cite by Name & Journal)

When a drug is newly approved or your case is borderline, cite the pivotal trial:

• FLAURA, FLAURA2, ADAURA (Tagrisso)
• MARIPOSA (Lazcluze + Rybrevant)
• CROWN (Lorbrena)
• KRYSTAL-1 (Krazati)
• CodeBreaK 100/200 (Lumakras)
• DESTINY-Breast04, DESTINY-Breast06 (Enhertu)
• CAPItello-291 (Truqap)
• INAVO120 (Itovebi)
• monarchE (Verzenio adjuvant)
• NATALEE (Kisqali adjuvant)
• MONALEESA-2/3/7 (Kisqali metastatic)
• ASCENT, TROPiCS-02 (Trodelvy)
• TROPION-Breast01 (Datroway)
• EV-302 (Padcev + Keytruda)
• SPOTLIGHT, GLOW (Vyloy)
• MIRASOL (Elahere)
• innovaTV 301 (Tivdak)
• RUBY (Jemperli)
• FRESCO-2 (Fruzaqla)
• BEACON (Braftovi + Erbitux)

Many of these were published in New England Journal of Medicine, Journal of Clinical Oncology, or Lancet Oncology—cite the journal, year, and first author if available in your oncologist's letter.

FDA Companion Diagnostic Approvals

• FoundationOne CDx (F1CDx): FDA-approved companion diagnostic for multiple genes/drugs.
• Guardant360 CDx: FDA-approved liquid biopsy CDx.
• MSK-IMPACT, Tempus xT, Caris MI Profile: widely used comprehensive panels; cite institutional validation studies or FDA recognition where applicable.

ASCO & Other Society Statements

• American Society of Clinical Oncology (ASCO) guidelines and provisional clinical opinions.
• Society for Immunotherapy of Cancer (SITC) consensus statements.
• American College of Radiology (ACR) Appropriateness Criteria for imaging and radiation modality selection.

Biomarker Testing Guidelines

• NCCN Guidelines for tumor biomarker testing (e.g., NCCN NSCLC recommends broad molecular profiling including NGS for advanced disease).
• CAP/IASLC/AMP molecular testing guideline updates (College of American Pathologists / International Association for the Study of Lung Cancer / Association for Molecular Pathology).

How to Argue Against Each Major Denial Template

"Experimental / Investigational"

Concrete steps:

1. Obtain the written denial letter and note the exact language and policy section cited.

2. Request your plan's medical policy bulletin for the drug or service (available on the insurer's provider portal or by calling member services). Look for the version number and effective date.

3. Ask your oncologist for a letter of medical necessity that includes:

- Your diagnosis, stage, biomarkers (e.g., EGFR exon 19 deletion, PD-L1 CPS 80%, BRCA2 mutation).

- The specific drug, dose, and regimen.

- FDA approval date and indication that matches your case (see list above).

- NCCN category (1, 2A, or 2B preferred recommendation) for your exact cancer type and clinical scenario.

- Reference to the pivotal trial by name and journal.

- Statement that the treatment is "standard of care and widely adopted in the oncology community."

4. Attach the FDA approval letter (available at accessdata.fda.gov) and the relevant NCCN guideline pages (if your oncologist's institution subscribes, they can print the compendium entry and guideline algorithm).

5. File a first-level appeal (usually must be submitted within 180 days of the denial; some states require expedited review for oncology—cite your state's external review law if time-sensitive).

6. Cite the plan's own policy: many medical policies state they will cover FDA-approved drugs or those in NCCN 1/2A—show that your case meets these criteria.

7. If denied again, request external review (independent review organization, IRO). In your external review letter, emphasize that the insurer's own policy contradicts the denial and that delaying cancer treatment risks progression and harm.

"Not Medically Necessary"

Concrete steps:

1. Identify the insurer's criteria (often buried in medical policy: "requires failure of X prior therapies" or "PD-L1 ≥50% only").

2. Document prior treatment failures if applicable—dates, regimens, scans showing progression.

3. Highlight your biomarkers: If you have a driver mutation (EGFR, ALK, ROS1, KRAS G12C, BRAF V600E, NTRK, RET, MET exon 14) or high PD-L1/TMB-high/MSI-high/dMMR, state that national guidelines prioritize targeted or immunotherapy in these populations, often as first-line treatment.

4. Oncologist letter: "Delaying [Drug X] to require trial of [older regimen Y] is contrary to NCCN guidelines, risks disease progression, and is not the standard of care for a patient with [biomarker/stage]."

5. Cite specific NCCN language: e.g., "NCCN NSCLC Guidelines v3.2024 list osimertinib (Tagrisso) as the preferred first-line regimen for EGFR exon 19 deletion, Category 1 evidence" or "NCCN Breast Cancer Guidelines v5.2024 include Enhertu as a preferred option for HER2-low metastatic breast cancer after endocrine therapy, based on DESTINY-Breast04."

6. If the plan requires "step therapy" and your state has a step-therapy override law (many do for cancer), your oncologist can file an override request certifying that the required step is medically inappropriate.

7. Peer-to-peer review: Request that the insurer's medical director speak directly with your oncologist. Often denials are overturned when the reviewing physician hears nuanced clinical context (performance status, comorbidities, rapidity of progression).

"Off-Label / Not FDA-Approved for Your Cancer Type"

Concrete steps:

1. Check the NCCN Compendium (your oncologist's office should have access). If the drug is listed for your cancer with a Category 1, 2A, or 2B recommendation, your plan is likely required to cover it under federal or state law.

2. Cite the legal standard: "Under the Medicare Modernization Act of 2003 §186 and the Affordable Care Act, anticancer drugs in the NCCN Compendium (or other CMS-recognized compendia) for off-label indications must be covered by Medicare Part D and many commercial plans." (Even if you have commercial insurance, many plans mirror this standard.)

3. Oncologist letter: "While [Drug] is FDA-approved for [Cancer A], it is also recognized in the NCCN Compendium with Category [1/2A/2B] recommendation for [Your Cancer B], supported by [Trial Name, Journal, Year]."

4. Attach compendium pages: Print the relevant entry showing your cancer type and the drug's category.

5. State laws: Some states (e.g., California, Maryland, Massachusetts) have explicit off-label coverage mandates for cancer drugs in peer-reviewed literature or recognized compendia—cite your state statute if applicable.

6. Alternative compendia: If NCCN does not list your scenario, check DrugDex (Micromedex), AHFS-DI (American Hospital Formulary Service Drug Information), or Clinical Pharmacology—these are also CMS-recognized. Peer-reviewed journal articles and society guidelines can supplement.

"Genomic Testing Not Covered / Too Broad"

Concrete steps:

1. Confirm FDA companion diagnostic status: FoundationOne CDx and Guardant360 CDx are FDA-approved companion diagnostics and should be covered when medically necessary (advanced/metastatic solid tumor).

2. Oncologist letter: "Comprehensive genomic profiling is standard of care per NCCN, ASCO, CAP/IASLC/AMP guidelines for stage IV [cancer type]. It identifies FDA-approved targeted therapies (e.g., EGFR, ALK, ROS1, BRAF, NTRK, RET, KRAS G12C inhibitors) and enrollment in precision-medicine trials."

3. Cite NCCN: NCCN NSCLC Guidelines recommend broad molecular profiling (NGS) for all patients with advanced nonsquamous or squamous NSCLC; NCCN Colon/Rectal Guidelines recommend extended RAS, BRAF, MSI, HER2, NTRK testing; NCCN Ovarian includes BRCA and HRR testing.

4. Medical necessity: Explain that single-gene tests are insufficient because 5–10% of lung cancers harbor rare actionable mutations (RET, MET exon 14, NTRK, KRAS G12C) and that repeat biopsies are often not feasible (tissue exhausted, patient frailty, liquid biopsy as alternative).

5. Cost-effectiveness argument: "Comprehensive NGS replaces 8–15 separate single-gene tests, reducing delay and overall cost."

6. Attach guidelines: Print the NCCN testing algorithm and the ASCO provisional clinical opinion on tumor mutational burden and PD-L1 as predictive biomarkers (if relevant).

"Radiation Modality Not Superior / Proton Therapy Experimental"

Concrete steps:

1. Know the high-evidence indications: Proton therapy is widely accepted (and often mandated by policy) for:

- Pediatric CNS and sarcoma tumors (reduced late effects, secondary malignancy risk).

- Base-of-skull tumors (chordoma, chondrosarcoma).

- Uveal melanoma.

- Hepatocellular carcinoma (especially large or central).

- Re-irradiation (head and neck, recurrent rectal, spine).

- Left-sided breast cancer in young women (cardiac sparing).

- Lung cancer near heart/esophagus (selective cases, compare dose-volume histograms).

2. Radiation oncologist letter with dosimetric comparison: "Comparative treatment plans demonstrate that proton therapy reduces mean heart dose from 8 Gy to 1.5 Gy, critical to minimize late cardiac toxicity in this 42-year-old patient with left breast cancer and BRCA1 mutation."

3. Cite ACR Appropriateness Criteria and the National Association for Proton Therapy (NAPT) model policy.

4. Pediatric cases: Emphasize neurocognitive, growth, and secondary cancer risks with photon therapy; cite Children's Oncology Group (COG) recommendations.

5. Peer-reviewed data: Reference institutional series or secondary analyses from NRG Oncology trials showing dosimetric or toxicity benefits.

6. If denied, external review is often successful for proton therapy in pediatric and base-of-skull cases, where evidence is strong.

When to Escalate: Peer-to-Peer, External Review, and Regulators

• Peer-to-peer review: Always request this during the internal appeal. Your oncologist speaks directly to the insurer's physician reviewer, often resolving misunderstandings about biomarkers, line of therapy, or guideline interpretation.
• Expedited/urgent appeal: If your cancer is progressing or you're in a treatment window (e.g., adjuvant chemotherapy must start within 60–90 days post-surgery), request an expedited review (most states require a decision within 72 hours for urgent cases). Use the words "urgent" and "imminent harm" in your appeal letter.
• External review (IRO): If the internal appeal is denied, you have the right to an independent external review in all states (federally mandated under the ACA for non-grandfathered plans). The IRO's decision is usually binding. File within the deadline (often 4–6 months from final internal denial). In your external review submission, restate all evidence, attach all letters and studies, and emphasize guideline concordance and standard of care.
• State insurance commissioner complaint: File a complaint with your state Department of Insurance if the insurer is delaying, not responding, or violating its own policy. This can trigger regulatory pressure.
• Department of Labor (self-insured ERISA plans): If your plan is self-insured (common for large employers), the DOL oversees ERISA; you can file a complaint if the plan is not following its own summary plan description or claims procedure.

What We Do

We help patients, families, and oncology practices build comprehensive, evidence-based appeal packets for cancer treatment denials—immunotherapy, targeted therapy, CAR-T, genomic testing, proton therapy, and off-label regimens. We track the latest FDA approvals, NCCN updates, and payer medical policies across the country, and we know which citations and arguments resonate in peer-to-peer and external review. If you're facing a denial, we can draft the appeal letter, coordinate with your oncologist, compile the clinical evidence, and guide you through expedited and external review processes. Time matters in cancer care—we work fast, and we focus on what wins.

---

Sources

1. NCCN Clinical Practice Guidelines in Oncology, National Comprehensive Cancer Network, www.nccn.org/guidelines (subscription required; accessed by oncologists and institutions).

2. NCCN Drugs & Biologics Compendium (NCCN Compendium), National Comprehensive Cancer Network, www.nccn.org/clinical-tools/compendia.

3. FDA Approved Drugs database, U.S. Food and Drug Administration, www.accessdata.fda.gov/scripts/cder/daf.

4. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer (FLAURA). N Engl J Med. 2018;378(2):113–125.

5. Wu YL, Dziadziuszko R, Ahn JS, et al. Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer (ADAURA adjuvant osimertinib). N Engl J Med. 2020;383(17):1711–1723.

6. Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC (FLAURA2). N Engl J Med. 2023;389(21):1935–1948.

7. Cho BC, Lu S, Srimuninnimit V, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC (MARIPOSA). J Clin Oncol. 2024;42(suppl):LBA8.

8. Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in Patients with ALK-Positive Non–Small-Cell Lung Cancer (CROWN). N Engl J Med. 2021;383(9):829–839.

9. Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer (DESTINY-Breast04). N Engl J Med. 2022;387(1):9–20.

10. Curigliano G, Hu X, Dent RA, et al. Trastuzumab Deruxtecan in HER2-Ultralow or HER2-Low, Hormone Receptor–Positive Metastatic Breast Cancer (DESTINY-Breast06). ESMO Congress 2024, LBA11.

11. Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer (CAPItello-291). N Engl J Med. 2023;388(22):2058–2070.

12. Juric D, Kalinsky K, Turner NC, et al. Inavolisib plus Palbociclib and Fulvestrant in PIK3CA-Mutated, Hormone Receptor–Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (INAVO120). SABCS 2023, abstract GS01-10.

13. Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib Combined with Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020;38(34):3987–3998.

14. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer (RIBOCICLIB). N Engl J Med. 2016;375(18):1738–1748.

15. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer (ASCENT). N Engl J Med. 2021;384(16):1529–1541.

16. Rugo HS, Bardia A, Marmé F, et al. Sacituzumab Govitecan in Hormone Receptor–Positive/HER2-Negative Metastatic Breast Cancer (TROPiCS-02). J Clin Oncol. 2023;41(17_suppl):LBA1001.

17. Kalinsky K, Oliveira M, Lustberg MB, et al. Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously Treated HR+/HER2− Metastatic Breast Cancer (TROPION-Breast01). SABCS 2024, abstract GS02-10.

18. Powles T, Valderrama BP, Gupta S, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer (EV-302). N Engl J Med. 2024;390(10):875–888.

19. Shitara K, Rha SY, Wyrwicz LS, et al. Zolbetuximab plus mFOLFOX6 in Patients with CLDN18.2-Positive, HER2-Negative, Untreated, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (SPOTLIGHT). Lancet. 2023;401(10389):1655–1668.

20. Moore KN, Oza AM, Colombo N, et al. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer (MIRASOL). N Engl J Med. 2023;389(23):2162–2174.

21. Monk BJ, Coleman RL, Fujiwara K, et al. Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer (innovaTV 301). N Engl J Med. 2024;390(17):1536–1548.

22. Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer (RUBY). N Engl J Med. 2023;388(23):2145–2158.

23. Dasari A, Lonardi S, Garcia-Carbonero R, et al. Fruquintinib versus Placebo in Patients with Refractory Metastatic Colorectal Cancer (FRESCO-2). Lancet. 2023;402(10395):41–53.

24. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer (BEACON). N Engl J Med. 2019;381(17):1632–1643.

25. Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Pub. L. 108–173, §186 (off-label anticancer use, compendia).

26. Patient Protection and Affordable Care Act, Pub. L. 111–148, §2713 (preventive services); external review provisions §2719.

27. American Society of Clinical Oncology (ASCO) Guidelines, www.asco.org/research-guidelines/quality-guidelines/guidelines.

28. College of American Pathologists / International Association for the Study of Lung Cancer / Association for Molecular Pathology (CAP/IASLC/AMP) molecular testing guidelines, J Thorac Oncol, updates 2013–2018.

29. American College of Radiology (ACR) Appropriateness Criteria, www.acr.org/Clinical-Resources/ACR-Appropriateness-Criteria.

30. FoundationOne CDx technical information, Foundation Medicine, www.foundationmedicine.com/test/foundationone-cdx.

31. Guardant360 CDx technical information, Guardant Health, guardant360cdx.com.

---

Disclaimer: This guide is educational and does not constitute legal or medical advice. Always work with your oncology team and consider consulting a patient advocate or attorney experienced in insurance appeals for complex cases. Regulations and coverage policies vary by state, plan, and year—verify current rules with your insurer and state Department of Insurance.